Do Drugs Given Expedited Approval Have More Safety Risks? GAO Says FDA Can't Tell
This article was originally published in The Pink Sheet Daily
Executive Summary
Findings could give pharmacovigilance prominence alongside 'breakthrough' and other speed mechanisms in legislative debate on agency reform.
You may also be interested in...
Postmarket Safety Signal Evaluation: US FDA ‘MAPPS’ Out New Approach
For drug sponsors, FDA's revised process could mean more public disclosures about potential safety risks and more regulatory actions to address those risks. CDER seeks to better leverage scientific and regulatory expertise, including in product quality and compliance, in investigating safety signals under the new policy manual, which also includes target timelines for action.
JAMA Study Continues Wave Of Accelerated Approval Criticism Amid Expansion Of Pathway
Sponsors are increasingly using the accelerated approval pathway, but research continues to be critical about its aspects.
FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades
Changes in legacy DARRTS system, transition to new platform and standardized format for annual report submission should improve FDA's tracking of postmarketing requirements, agency tells Office of the Inspector General.